Holmium-166 Radioembolization

Abstract

Radioembolization is usually performed with microspheres containing yttrium-90 (⁹⁰Y). Holmium-166 (¹⁶⁶Ho)-microspheres were developed as an alternative new product for radioembolization. The unique characteristics of ¹⁶⁶Ho-microspheres allow for improved imaging possibilities. They can be visualized and quantified, already at low numbers and activities, to predict treatment distribution using ¹⁶⁶Ho-microspheres at scout quantity during pre-treatment simulation. The option to reliably predict the distribution of microspheres provides physicians control over the treatment, allowing them to select and treat patients with a personalized treatment plan. Safety and efficacy were established in several clinical studies. ¹⁶⁶Ho-microspheres radioembolization aims to optimize individualized treatment planning in order to improve treatment outcomes.

Keywords

radioembolization - holmium - liver

Publikationsverlauf

Eingereicht: 03. Dezember 2020

Angenommen: 22. Dezember 2020

Artikel online veröffentlicht:
15. April 2021

• References

• 1 Elschot M, Nijsen JF, Dam AJ, de Jong HW. Quantitative evaluation of scintillation camera imaging characteristics of isotopes used in liver radioembolization. PLoS One 2011; 6 (11) e26174
• 2 van de Maat GH, Seevinck PR, Elschot M. et al. MRI-based biodistribution assessment of holmium-166 poly(L-lactic acid) microspheres after radioembolisation. Eur Radiol 2013; 23 (03) 827-835
• 3 Nijsen JF, Seppenwoolde JH, Havenith T, Bos C, Bakker CJ, van het Schip AD. Liver tumors: MR imaging of radioactive holmium microspheres--phantom and rabbit study. Radiology 2004; 231 (02) 491-499
• 4 Elschot M, Lam MG, van den Bosch MA, Viergever MA, de Jong HW. Quantitative Monte Carlo-based 90Y SPECT reconstruction. J Nucl Med 2013; 54 (09) 1557-1563
• 5 Smits ML, Elschot M, van den Bosch MA. et al. In vivo dosimetry based on SPECT and MR imaging of ¹⁶⁶Ho-microspheres for treatment of liver malignancies. J Nucl Med 2013; 54 (12) 2093-2100
• 6 Braat AJAT, Prince JF, van Rooij R, Bruijnen RCG, van den Bosch MAAJ, Lam MGEH. Safety analysis of holmium-166 microsphere scout dose imaging during radioembolisation work-up: a cohort study. Eur Radiol 2018; 28 (03) 920-928
• 7 Elschot M, Nijsen JF, Lam MG. et al. (⁹⁹m)Tc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with ¹⁶⁶Ho-microspheres. Eur J Nucl Med Mol Imaging 2014; 41 (10) 1965-1975
• 8 Smits MLJ, Dassen MG, Prince JF. et al. The superior predictive value of ¹⁶⁶Ho-scout compared with ^99mTc-macroaggregated albumin prior to ¹⁶⁶Ho-microspheres radioembolization in patients with liver metastases. Eur J Nucl Med Mol Imaging 2020; 47 (04) 798-806
• 9 Smits MLJ, Nijsen JFW, van den Bosch MAAJ. et al. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study. Lancet Oncol 2012; 13 (10) 1025-1034
• 10 Prince JF, van den Bosch MAAJ, Nijsen JFW. et al. Efficacy of radioembolization with ¹⁶⁶Ho-microspheres in salvage patients with liver metastases: a phase 2 study. J Nucl Med 2018; 59 (04) 582-588
• 11 Braat AJAT, Kwekkeboom DJ, Kam BLR. et al. Additional hepatic ¹⁶⁶Ho-radioembolization in patients with neuroendocrine tumours treated with ¹⁷⁷Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial). BMC Gastroenterol 2018; 18 (01) 84
• 12 Braat AJAT, Bruijnen RCG, van Rooij R. et al. Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study. Lancet Oncol 2020; 21 (04) 561-570
• 13 Pasciak AS, McElmurray JH, Bourgeois AC, Heidel RE, Bradley YC. The impact of an antireflux catheter on target volume particulate distribution in liver-directed embolotherapy: a pilot study. J Vasc Interv Radiol 2015; 26 (05) 660-669
• 14 Arepally A, Chomas J, Kraitchman D, Hong K. Quantification and reduction of reflux during embolotherapy using an antireflux catheter and tantalum microspheres: ex vivo analysis. J Vasc Interv Radiol 2013; 24 (04) 575-580
• 15 van den Hoven AF, Prince JF, Bruijnen RC. et al. Surefire infusion system versus standard microcatheter use during holmium-166 radioembolization: study protocol for a randomized controlled trial. Trials 2016; 17 (01) 520
• 16 van Roekel C, van den Hoven AF, Bastiaannet R. et al. Use of an anti-reflux catheter to improve tumor targeting for holmium-166 radioembolization-a prospective, within-patient randomized study. Eur J Nucl Med Mol Imaging 2020
• 17 van Roekel C, Smits MLJ, Prince JF, Bruijnen RCG, van den Bosch MAAJ, Lam MGEH. Quality of life in patients with liver tumors treated with holmium-166 radioembolization. Clin Exp Metastasis 2020; 37 (01) 95-105
• 18 Bastiaannet R, van Roekel C, Smits MLJ. et al. First evidence for a dose-response relationship in patients treated with ¹⁶⁶Ho radioembolization: a prospective study. J Nucl Med 2020; 61 (04) 608-612
• 19 van Roekel C, Bastiaannet R, Smits MLJ. et al. Dose-effect relationships of holmium-166 radioembolization in colorectal cancer. J Nucl Med 2021; 62 (02) 272-279
• 20 Stella M, Braat A, Lam M, de Jong H, van Rooij R. Quantitative ¹⁶⁶Ho-microspheres SPECT derived from a dual-isotope acquisition with ^99mTc-colloid is clinically feasible. EJNMMI Phys 2020; 7 (01) 48
• 21 Braat A, Van Rooij R, Van den Bosch MA, Lam MG. Improved dosimetry in radioembolization using a dual isotope SPECT/CT protocol with ¹⁶⁶Ho-microspheres and 99mTc-stannous phytate: a proof of concept. J Nucl Med 2016; 57 (02) 1423